Join to view full profile
22 S Greene StFl 1Baltimore, MD 21201
Phone+1 410-328-2575
Dr. Rosner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Samuel Rosner is an oncology specialist located in Baltimore, MD, with a subspecialty focus on thoracic cancer. He completed his residency in internal medicine at Johns Hopkins University/Bayview Medical Center in 2020 and graduated from Albert Einstein College of Medicine in 2017. His expertise includes lung cancer, immune checkpoint blockade, and kras-mutant non-small cell lung cancer (NSCLC). Dr. Rosner has several publications, including works on tarlatamab administration, STK11 co-mutation status, antibody-drug conjugates, and immunotherapy response in lung cancer, which have been cited by other publications.
Education & Training
Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2017 - 2020
Albert Einstein College of MedicineClass of 2017
Certifications & Licensure
MD State Medical License 2021 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC.Graeme Fenton, Annie L Zhang, Sharon Zhong, Curtis Tatsuoka, Michelle Sittig
JTO Clinical and Research Reports. 2026-04-01 - A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.Bingnan Zhang, Laura Alder, Samuel Rosner, Aakash Desai, Alissa J Cooper
Lung Cancer. 2026-01-01 - 10 citationsDivergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
Clinical Cancer Research. 2025-01-17
Press Mentions
Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023- Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung CancerFebruary 15th, 2023
- Neoadjuvant Nivolumab Shows Long-Term Benefit in Patients with Non-Small Cell Lung CancerFebruary 15th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
